Efficacy of pharmacist intervention for a patient who takes incretin modulator.

Efficacy of pharmacist intervention for a patient who takes incretin modulator. - Efficacy of pharmacist intervention for a patient who takes incretin modulator.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050659

Enrollment

Registered

2023-04-01

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

sleep guidance exercise guidance manage side effects

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)A person who uses DPP-4 inhibitor or GLP-1 receptor agonist for more than 6 months. (2)Over 18 years of age.

Exclusion criteria

Exclusion criteria: (1)A person who already running sleep guidance and exercise guidance. (2)When if give exercise guidance, A person who occurs cardiovascular disease, retinopathy, nephropathy, neuropathy and orthopedic disease.

Design outcomes

Primary

Measure	Time frame
body weight	—

Secondary

Measure	Time frame
(1)HbA1c (2)body weight (3)adherence (4)side effects	—

Countries

Japan

Contacts

Public ContactYumeka WASHIO

Chiba Pharmaceutical Association Drug Information Center

drug-info@c-yaku.or.jp043-247-4401

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026